New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics.

IF 15.1 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Annual review of medicine Pub Date : 2023-01-27 DOI:10.1146/annurev-med-043021-014919

Ania M Jastreboff, Robert F Kushner

引用次数: 8

Abstract

Nearly half of Americans are projected to have obesity by 2030, underscoring the pressing need for effective treatments. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) represent the first agents in a rapidly evolving, highly promising landscape of nascent hormone-based obesity therapeutics. With the understanding of the neurobiology of obesity rapidly expanding, these emerging entero-endocrine and endo-pancreatic agents combined or coformulated with GLP-1 RAs herald a new era of targeted, mechanism-based treatment of obesity. This article reviews GLP-1 RAs in the treatment of obesity and previews the imminent future of nutrient-stimulated hormone-based anti-obesity therapeutics.

查看原文本刊更多论文

肥胖症治疗的新领域:GLP-1和新生的营养刺激激素疗法。

预计到2030年，将近一半的美国人将患有肥胖症，这凸显了对有效治疗的迫切需求。胰高血糖素样肽1受体激动剂(GLP-1 RAs)代表了新兴的基于激素的肥胖治疗快速发展、前景光明的第一种药物。随着对肥胖神经生物学的认识迅速扩大，这些新兴的肠内分泌和胰腺内药物与GLP-1 RAs联合或共配预示着靶向性、基于机制的肥胖治疗的新时代。本文综述了GLP-1 RAs在肥胖治疗中的作用，并展望了基于营养刺激激素的抗肥胖治疗的未来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annual review of medicine 医学-医学：内科

CiteScore

24.90

自引率

0.00%

发文量

期刊介绍： The Annual Review of Medicine, which has been published since 1950, focuses on important advancements in diverse areas of medicine. These include AIDS/HIV, cardiology, clinical pharmacology, dermatology, endocrinology/metabolism, gastroenterology, genetics, immunology, infectious disease, neurology, oncology/hematology, pediatrics, psychiatry, pulmonology, reproductive medicine, and surgery. The journal's current volume has transitioned from a gated access model to an open access model through the Annual Reviews' Subscribe to Open program. All articles published in the journal are now available under a CC BY license.